Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829116 | 0.90 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4SLC18A2 | |
| SCHEMBL10262984 | 0.88 | SLC6A3 (0.56) | SLC6A3SLC6A2SLC6A4MAPTPKM | |
| SCHEMBL4757346 | 0.88 | MAPT (0.46) | SLC6A3SLC6A2SLC6A4MAPTPKM | |
| SCHEMBL5006473 | 0.85 | ALDH1A1 (0.45) | SLC6A3SLC6A2SLC6A4MAPTPKM | |
| SCHEMBL14611180 | 0.84 | SLC6A2 (0.49) | SLC6A3SLC6A2SLC6A4MAPTPKM | |
| SCHEMBL14065593 | 0.83 | MAPT (0.54) | SLC6A3SLC6A2SLC6A4MAPTPKM | |
| SCHEMBL14376312 | 0.83 | MAPT (0.54) | SLC6A3SLC6A2SLC6A4MAPTPKM | |
| SCHEMBL14065598 | 0.83 | MAPT (0.54) | SLC6A3SLC6A2SLC6A4MAPTPKM | |
| SCHEMBL1969776 | 0.82 | SLC6A4 (0.63) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8498107 | 0.82 | SLC6A2 (0.61) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119525-A1 | METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS | MOUNT SINAI SCHOOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119525-A1 | METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS | MOUNT SINAI SCHOOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090186874-A1 | Carboxamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090035784-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090035784-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1789437-A4 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | SINAI SCHOOL MEDICINE (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1789437-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | Mount Sinai School of Medicine of New York University (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1705176-A1 | CARBOXAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006015365-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035784-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | NPC1L1, NPC1, SREBF2 | SLC6A3 1464/4885SLC6A2 813/4885SLC6A4 1745/4885 |
| US-20090186874-A1 | Carboxamide derivative and use thereof | NTSR2, NTSR1, CNR2 | SLC6A3 814/4885SLC6A2 515/4885SLC6A4 578/4885 |
| US-20100119525-A1 | METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS | NPC1L1, LIPA, LPL | SLC6A3 3538/4885SLC6A2 1809/4885SLC6A4 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.